Refine by
Disease Patient Articles & Analysis
590 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced release of its new line of Human Hybrid IgM Control Monoclonal Antibodies for research applications, covering a range of diseases such as CMV, HSV, MeV, MuV, RuV, and VZV.Characteristic disease state sera are serum samples derived from individuals with ...
Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and ...
By offering a comprehensive selection of Circulatory System Tissue Microarrays with diverse patient samples and disease states, CD BioSciences aims to empower researchers to gain deeper insights into these critical areas of human health and conduct more efficient and comprehensive studies. ...
Biomedical Polymers Biomedical polymers have and still continue to play an important role in how we support and treat patients with various diseases through their use in tissue and blood interacting medical devices and drug delivery systems. ...
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and ...
ByeTheRNA
Fungal Disease Awareness Week (FDAW) kicks off today and runs through the 22nd. The Centers for Disease Control and Prevention (CDC) created FDAW to highlight the importance of recognizing, treating, and preventing serious fungal diseases. According to the CDC: Many people are affected by fungal diseases at different points in their lives, whether dealing with a somewhat common ringworm ...
Baseline disease characteristics in patients maintaining q12 and q16 dosing with aflibercept 8 mg versus patients with shortened treatment intervals: A Phase 3 PULSAR post hoc analysis Poster presentation # 2238-C0192 April 24, 2023; 15.15-17.00 EST In a subgroup analysis from the phase III trial PULSAR the treatment effect on the primary ...
ByBayer AG
They are more in need of remodelling of the skeletal support structure. Pregnant women, patients with severe heart disease and diabetes, such people should be guided by their doctor in choosing a suitable beauty solution. ...
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the ...
ByBayer AG
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in ...
ByBayer AG
Nubeqa is already approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
“Extended treatment intervals meet an important patient need by significantly reducing the disease burden for patients with exudative retinal diseases. ...
ByBayer AG
Applying induced pluripotent stem cell (iPSC) technology, patient-cell derived 3D micro tissues exhibiting hereditary cardiac diseases are mass-produced in micro wells. ...
Application of induced pluripotent technology allows to fabricate tissues in diseased states, e.g., hereditary cardiac diseases, cardiac fibrosis, cancer and orphan diseases. ...
“The growing data from the ARASENS trial continue to demonstrate darolutamide’s value in treating patients with mHSPC. The benefit is especially in those with high-volume or high-risk disease. ...
ByBayer AG
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
ImmunogenX is pleased to report the successful completion of the CeliacShield trial (NCT03585478), focused on treating celiac disease (CeD) patients, will be published in the premier journal Gastroenterology and is entitled: Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease Exposed ...
“Even when blood glucose levels and blood pressure are well-controlled, the risk of kidney disease progression and cardiovascular events remains high in patients with chronic kidney disease and type 2 diabetes,” said Dr. ...
ByBayer AG
TMAs lesions can be associated with many diseases and some genetic disorders linked to aHUS. Molecular diagnoses, in particular in genes associated with alternative complement pathway regulation, make it possible to identify patients that suffer from this condition as well as informing on possible therapeutic options for TMA/aHUS. ...
This makes Revacept particularly suitable for the secondary prevention of strokes in patients with carotid stenosis, who have the highest risk of recurrent strokes among stroke patients and require intensive therapy." Following the positive results of all previous studies with Revacept, including patients with coronary heart ...